Cargando…

lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma

Integrin alpha L (ITGAL) seemed to play a critical role in carcinogenesis and immune regulation. Nevertheless, the effects of ITGAL on non-small cell lung cancer (NSCLC) remain elusive. The present paper intended to determine the effects of ITGAL in NSCLC via the integration of bioinformatic analyse...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiang, Xiao, GuangJun, Li, Na, Jiang, Xiulin, Li, Chunhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258036/
https://www.ncbi.nlm.nih.gov/pubmed/37256932
http://dx.doi.org/10.18632/aging.204756
_version_ 1785057407825608704
author Wang, Qiang
Xiao, GuangJun
Li, Na
Jiang, Xiulin
Li, Chunhong
author_facet Wang, Qiang
Xiao, GuangJun
Li, Na
Jiang, Xiulin
Li, Chunhong
author_sort Wang, Qiang
collection PubMed
description Integrin alpha L (ITGAL) seemed to play a critical role in carcinogenesis and immune regulation. Nevertheless, the effects of ITGAL on non-small cell lung cancer (NSCLC) remain elusive. The present paper intended to determine the effects of ITGAL in NSCLC via the integration of bioinformatic analyses. In this study, we found that the mRNA and protein levels of ITGAL were downregulated in NSCLC tissues. Significantly, low ITGAL expression was related to poorer prognosis and increased malignancy of NSCLC. In addition, GO analysis and KEGG pathway analysis revealed that the coexpressed genes of ITGAL were predominantly associated with various immune-associated signaling pathways, like the T cell receptor signaling pathway, Th17 cell differentiation, chemokine signaling pathway, and NF-κB signaling pathway. Our result indicated that lncRNA-mediated downregulation of integrin alpha L expression was tightly related to immunocyte infiltration, immune modulators, and chemotactic factors in NSCLC, which potentially serves as a biomarker for clinical prognosis prediction and immunotherapy of NSCLC. This is the first comprehensive analysis of ITGAL in the prognosis, immune microenvironment, and immunotherapy of lung adenocarcinoma. ITGAL are promising biomarkers for predicting clinical outcomes and immunotherapy responses in patients with NSCLC.
format Online
Article
Text
id pubmed-10258036
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-102580362023-06-13 lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma Wang, Qiang Xiao, GuangJun Li, Na Jiang, Xiulin Li, Chunhong Aging (Albany NY) Research Paper Integrin alpha L (ITGAL) seemed to play a critical role in carcinogenesis and immune regulation. Nevertheless, the effects of ITGAL on non-small cell lung cancer (NSCLC) remain elusive. The present paper intended to determine the effects of ITGAL in NSCLC via the integration of bioinformatic analyses. In this study, we found that the mRNA and protein levels of ITGAL were downregulated in NSCLC tissues. Significantly, low ITGAL expression was related to poorer prognosis and increased malignancy of NSCLC. In addition, GO analysis and KEGG pathway analysis revealed that the coexpressed genes of ITGAL were predominantly associated with various immune-associated signaling pathways, like the T cell receptor signaling pathway, Th17 cell differentiation, chemokine signaling pathway, and NF-κB signaling pathway. Our result indicated that lncRNA-mediated downregulation of integrin alpha L expression was tightly related to immunocyte infiltration, immune modulators, and chemotactic factors in NSCLC, which potentially serves as a biomarker for clinical prognosis prediction and immunotherapy of NSCLC. This is the first comprehensive analysis of ITGAL in the prognosis, immune microenvironment, and immunotherapy of lung adenocarcinoma. ITGAL are promising biomarkers for predicting clinical outcomes and immunotherapy responses in patients with NSCLC. Impact Journals 2023-05-31 /pmc/articles/PMC10258036/ /pubmed/37256932 http://dx.doi.org/10.18632/aging.204756 Text en Copyright: © 2023 Wang et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Wang, Qiang
Xiao, GuangJun
Li, Na
Jiang, Xiulin
Li, Chunhong
lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma
title lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma
title_full lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma
title_fullStr lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma
title_full_unstemmed lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma
title_short lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma
title_sort lncrna pcbp1-as1 mediated downregulation of itgal as a prognostic biomarker in lung adenocarcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258036/
https://www.ncbi.nlm.nih.gov/pubmed/37256932
http://dx.doi.org/10.18632/aging.204756
work_keys_str_mv AT wangqiang lncrnapcbp1as1mediateddownregulationofitgalasaprognosticbiomarkerinlungadenocarcinoma
AT xiaoguangjun lncrnapcbp1as1mediateddownregulationofitgalasaprognosticbiomarkerinlungadenocarcinoma
AT lina lncrnapcbp1as1mediateddownregulationofitgalasaprognosticbiomarkerinlungadenocarcinoma
AT jiangxiulin lncrnapcbp1as1mediateddownregulationofitgalasaprognosticbiomarkerinlungadenocarcinoma
AT lichunhong lncrnapcbp1as1mediateddownregulationofitgalasaprognosticbiomarkerinlungadenocarcinoma